BioMarin Announces Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $99 at RBC Capital
October 26, 2018 7:09 AM EDTRBC Capital analyst Kennen MacKay raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $99.00 (from $98.00) while maintaining a Sector Perform rating following results.
The analyst notes strong Q3 with top/bottom line beats and tantalizing hints at pipeline updates at the upcoming Nov7 RnD Day.
... More
BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
October 25, 2018 4:10 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of... More
